FDA approves new alternative standard related to mammography report assessments

FDA halts public release of Complete Response Letters, following citizen petition

FDA will temporarily stop publicly releasing rejection letters as it evaluates potential response to a citizen petition issued by an unnamed pharmaceutical company challenging the legality of the practice.

July 10, 2026

Vol.52 No.27

By Claire Marie Porter

Cancer Policy

FDA proposes rule to hold foreign tobacco companies to U.S. standards

FDA has issued a proposed rule to require both foreign and domestic tobacco manufacturers to register their facilities and list their products with the agency. This closes a regulatory gap, holding overseas e-cigarette and tobacco makers to the same standards as U.S. companies.

July 10, 2026

Vol.52 No.27

By Claire Marie Porter

Clinical Roundup

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Breast cancers diagnosed during the first three years after childbirth, particularly within the first year, may be biologically more aggressive than similar cancers in women who have never given birth, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

For people at high risk of developing breast cancer, yearly mammograms may not be enough to detect tumors early. To make earlier diagnosis easier, a Massachusetts Institute of Technology team has developed portable detectors based on ultrasound, which could be used much more frequently. The team reports that they have improved the resolution of the images produced by their system, making it easier to spot potential tumors, as well as cysts and microcalcifications.

July 10, 2026

Vol.52 No.27

Cancer Policy

FDA allows ZYN nicotine pouches to make marketing claim: ZYN is safer than cigarettes

FDA is allowing ZYN nicotine pouches, a tobaccoless product that has soared in popularity since in recent years, to make the claim that its products are safer than cigarettes.

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

MammaPrint + BluePrint can help identify a subset of patients with hormone receptor positive, HER2-negative early-stage breast cancer most likely to benefit from anthracycline-based chemotherapy, according to the results of the prospective FLEX Study (NCT03053193).

July 02, 2026

Vol.52 No.26

FDA approves new alternative standard related to mammography report assessments

YOU MAY BE INTERESTED IN

FDA halts public release of Complete Response Letters, following citizen petition

FDA proposes rule to hold foreign tobacco companies to U.S. standards

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

FDA allows ZYN nicotine pouches to make marketing claim: ZYN is safer than cigarettes

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login